Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer

Journal of Clinical Investigation(2022)10.1172/jci150517Source: DataRank Database

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer is a research paper published in Journal of Clinical Investigation (2022). On theSindex it has a DataRank of 0. It has been cited 46 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access46 citations

Download PDF

Cite:

Linked data & code

nct pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)OA: goldTopics (38)IDs (PubMed, PMC)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Justus M. Huelse,Dmitri Kireev ORCID,Zikang Tan,Luxiao Chen ORCID,Subir Goyal ORCID

Live enrichment

PubMed:35708914 PMC:PMC9337831

National Cancer Institute of the National Institutes of Health

Grant: P50CA217691

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: P30 CA016086

NCI NIH HHS

Grant: P30 CA138292

National Institutes of Health

Grant: 1P50CA217691-01A1

Emory University Lung Cancer SPORE

National Institutes of Health

Grant: 5P30CA138292-11

Winship Cancer Institute Cancer Center Support Grant

goldLicense: CC BY

publisherhttps://www.jci.org/articles/view/150517/files/pdf

Unpaywallhttp://www.jci.org/articles/view/150517/files/pdf

Europe_PMChttps://europepmc.org/articles/PMC9337831

Europe_PMChttps://europepmc.org/articles/PMC9337831?pdf=render

https://doi.org/10.1172/jci150517

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

Cell Line, TumorHumansCarcinoma, Non-Small-Cell LungLung NeoplasmsAcrylamidesAniline CompoundsPyrimidinesIndolesProtein Kinase InhibitorsDrug Resistance, NeoplasmMutationPhosphatidylinositol 3-KinasesErbB Receptorsc-Mer Tyrosine Kinase

Keywords

Cell biologyLung cancerProtein kinasesDrug therapyOncologyAcrylamidesAniline CompoundsIndolesLung Neoplasmsc-Mer Tyrosine KinaseRErbB ReceptorsPhosphatidylinositol 3-KinasesPyrimidinesDrug Resistance, NeoplasmCarcinoma, Non-Small-Cell LungCell Line, TumorMutationMedicineHumansProtein Kinase InhibitorsResearch Article

Sustainable Development Goals

SDG 3: 3. Good health